14:34 EST Edgewise moves off lows after stating FDA warning unrelated to company
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise should be bought on weakness as ARCH not likely FDA focus, says Truist
- Edgewise falls after FDA posts Warning Letter to trial investigator
- Edgewise Therapeutics price target raised to $50 from $33 at Truist
- Edgewise Therapeutics initiated with an Outperform at Evercore ISI
- Edgewise Therapeutics Reports Q3 Progress in Muscle Disease Trials